re MNTAs tech. is not required to fulfill scientific issues
Than why hasn't the two year head start on filing that Teva and Amphastar hold resulted in a tentative ANDA approval pending the Paragraph IV challenge?
The game changing event here may well have been the heparin contamination problem and how that could raise the bar to full characterization for ANDA approval.
Market Data 
Markets 
AI
